Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemia
暂无分享,去创建一个
D. Basanta | A. Marusyk | A. Dhawan | J. Taylor-King | E. Padron | Artem Kaznatcheev | Vincent L. Cannataro | Lin L. Liu | R. V. Velde | N. Yoon | E. Baratchart | D. Grimes | D. Myroshnychenko
[1] M. Hochberg,et al. Spatial competition constrains resistance to targeted cancer therapy , 2017, Nature Communications.
[2] Jacob G. Scott,et al. Optimal Therapy Scheduling Based on a Pair of Collaterally Sensitive Drugs , 2017, Bulletin of Mathematical Biology.
[3] David Basanta,et al. Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.
[4] Omer Dushek,et al. Architecture of a minimal signaling pathway explains the T-cell response to a 1 million-fold variation in antigen affinity and dose , 2016, Proceedings of the National Academy of Sciences.
[5] David Basanta,et al. Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature , 2016, British Journal of Cancer.
[6] R. Muschel,et al. Correction to ‘Estimating oxygen distribution from vasculature in three-dimensional tumour tissue’ , 2016, Journal of The Royal Society Interface.
[7] M. Stratton,et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents , 2016, Nature Communications.
[8] D. Steensma,et al. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) , 2016, Clinical Cancer Research.
[9] David Robert Grimes,et al. The Role of Oxygen in Avascular Tumor Growth , 2016, bioRxiv.
[10] M. Archetti,et al. Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer , 2015, Proceedings of the National Academy of Sciences.
[11] Alexander G. Fletcher,et al. Oxygen consumption dynamics in steady-state tumour models , 2014, Royal Society Open Science.
[12] K. Polyak,et al. Non-cell autonomous tumor-growth driving supports sub-clonal heterogeneity , 2014, Nature.
[13] B. Wouters,et al. Hypoxia signaling and the metastatic phenotype. , 2014, Current molecular medicine.
[14] Sergei A. Vinogradov,et al. Direct measurement of local oxygen concentration in the bone marrow of live animals , 2014, Nature.
[15] Timo R. Maarleveld,et al. StochPy: A Comprehensive, User-Friendly Tool for Simulating Stochastic Biological Processes , 2013, PloS one.
[16] David Basanta,et al. Edge effects in game-theoretic dynamics of spatially structured tumours , 2013, Journal of The Royal Society Interface.
[17] David Basanta,et al. Exploiting evolution to treat drug resistance: combination therapy and the double bind. , 2011, Molecular pharmaceutics.
[18] B. Bernstein,et al. Heterodimeric JAK-STAT Activation as a Mechanism of Persistence to JAK2 Inhibitor Therapy , 2011, Nature.
[19] Jacob G. Scott,et al. Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game , 2011, British Journal of Cancer.
[20] Xin Lu,et al. Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis , 2010, Clinical Cancer Research.
[21] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[22] Hannah H. Chang,et al. Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.
[23] P. Vaupel,et al. Hypoxia in cancer: significance and impact on clinical outcome , 2007, Cancer and Metastasis Reviews.
[24] B. Kholodenko. Cell-signalling dynamics in time and space , 2006, Nature Reviews Molecular Cell Biology.
[25] Annie Z. Tremp. Malaria: Plasmodium develops in lymph nodes , 2006, Nature Reviews Microbiology.
[26] G. Qian,et al. JAK—STAT signaling pathway in pulmonary arterial smooth muscle cells is activated by hypoxia , 2005, Cell biology international.
[27] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[28] J F Gross,et al. Analysis of oxygen transport to tumor tissue by microvascular networks. , 1993, International journal of radiation oncology, biology, physics.
[29] I. Tannock,et al. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. , 1972, The British journal of radiology.
[30] L. H. Gray,et al. The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.
[31] L. H. Gray,et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.
[32] W. F. Bodmer,et al. Modelling the consequences of interactions between tumour cells. , 1997, British Journal of Cancer.
[33] J F Gross,et al. Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. , 1995, Acta oncologica.